Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop

Area of Science:

• Virology
• Immunology
• Biostatistics
• Clinical Trials

Background:

• Human immunodeficiency virus (HIV) research relies on laboratory markers (e.g., HIV RNA, CD4+ cell counts) as surrogate endpoints in clinical studies.
• Unresolved statistical issues complicate the interpretation and application of these markers in clinical trial design, analysis, and patient management.
• The National Institute of Allergy and Infectious Diseases (NIAID) sponsored a workshop to address these statistical challenges.

Purpose of the Study:

• To summarize discussions and position statements from a workshop on statistical issues concerning HIV surrogate endpoints.
• To clarify the relationship between HIV laboratory markers and clinical outcomes.
• To guide the selection of appropriate endpoints and analytical methods for HIV clinical studies.

Main Methods:

• A workshop format involving statisticians and clinicians.
• Debate sessions addressing specific questions on HIV surrogate endpoints.
• Summarization of debaters' positions and outlined consensus conclusions.

Main Results:

• Key statistical issues in using HIV RNA and CD4+ cell counts as surrogate endpoints were explored.
• The relationship between laboratory markers and clinical endpoints was debated.
• Discussions aimed to clarify endpoint selection and analysis methods for HIV clinical trials.

Conclusions:

• The workshop provided clarity on several statistical issues related to HIV surrogate endpoints.
• Further consideration of highlighted problems is encouraged to improve the assessment of future HIV therapies.
• Consensus was reached on various aspects, though final answers remain under development.